Cipla EU to invest an additional EUR 3 million in Ethris

Mumbai, India, Munich, Germany - Cipla Limited today announced that its wholly-owned subsidiary in United Kingdom, Cipla (EU) Limited (hereinafter together referred as 'Cipla') will invest an additional EUR 3 million in Ethris GmbH ('Ethris'), a global leader in delivering mRNAs directly to the respiratory system.

This additional investment through a convertible loan will accelerate Cipla's participation in the mRNA space.

Cipla had earlier invested EUR 15 million in Ethris in 2022. This additional investment reaffirms Cipla's confidence in Ethris's proprietary mRNA platform and its potential for patients in emerging markets. Together, Cipla and Ethris are working towards a long-term strategic partnership to fast-track innovative mRNA-based treatments. During the COVID-19 pandemic, mRNA vaccines gained importance due to the first regulatory approvals for SARS-CoV-2. mRNA-based medicines have a huge potential in several indications as infectious disease vaccines, therapeutic cancer vaccines, and protein replacement therapies.

Umang Vohra, Managing Director & Global Chief Executive Officer of Cipla, said, 'At Cipla, we strive to dial-up our focus and investment towards innovative modalities and bring new age therapies to emerging countries, including India. The follow-on investment in Ethris will help get cutting-edge healthcare solutions like mRNA-based therapies to the Global South. As we lead Cipla ahead, we will continue to work towards building an innovative future and build brands that re-enforce our ethos of 'caring for life'.'

Dr. Carsten Rudolph, CEO of Ethris, added, 'The additional investment by Cipla further validates the broad potential of our platform and Ethris' innovative approaches to developing respiratory RNA-based medicines. We deeply value this ongoing relationship to bring effective solutions to developing countries. The capital will enable us to continue advancing our pipeline and we look forward to providing an update on our lead program in the near term.'

About Cipla

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective, and CNS segments are well-known. Our 47 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Feb'24), 1st in the pharma prescription market in South Africa (IQVIA MAT Feb'24), and 4th largest by prescription in the US Gx inhalation products (IQVIA MAT Feb'23). For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility, and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers, and all stakeholders.

About Ethris

Ethris has paved a new path from genes to therapeutic proteins, using its proprietary RNA and lipidoid nanoparticle technology platform to discover, design and develop innovative therapies. With more than a decade as an mRNA pioneer, Ethris is a global leader in delivering stabilized mRNAs directly to the respiratory system via optimised formulation and nebulisation technologies. The company is rapidly advancing its mRNA pipeline of immuno-modulation, protein replacement therapies, and differentiated vaccines, with the ultimate goal of improving patients' lives.

Contact:

Heena Kanal

Email: [e-mail]

Ajinkya Pandharkar

Email: [e-mail]

Dr. Philipp Schreppel

Tel: [phone]

Email: [e-mail]

(C) 2024 Electronic News Publishing, source ENP Newswire